Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Dysport Therapeutic | abobotulinumtoxinA | Upper limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adlyxine | lixisenatide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tresiba | insulin degludec | Diabetes mellitus, Type 1 & 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Galafold | migalastat | Fabry Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Maviret | glecaprevir pibrentasvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia (pediatric) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Izba | travoprost ophthalmic solution | Glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | Daratumumab | Multiple Myeloma (second-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ocrevus | ocrelizumab | multiple sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete | ||
| Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Active |
Last Updated : April 28, 2024